Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship

Student Dissertations, Theses and Papers

2015

Does a structured exercise intervention of at least
ten weeksimprove the distance walked in a 6
minute walking test(6MWT) in patients with
pulmonary arterial hypertensioncurrently on
optimized medical control compared to
patientswho do not exercise?
Peter M. Gdovin
Philadelphia College of Osteopathic Medicine, Petergd@pcom.edu

Follow this and additional works at: http://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Medicine and Health Sciences Commons
Recommended Citation
Gdovin, Peter M., "Does a structured exercise intervention of at least ten weeksimprove the distance walked in a 6 minute walking
test(6MWT) in patients with pulmonary arterial hypertensioncurrently on optimized medical control compared to patientswho do
not exercise?" (2015). PCOM Physician Assistant Studies Student Scholarship. Paper 222.

This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.

	
  

Does a structured exercise intervention of at least ten weeks
improve the distance walked in a 6 minute walking test
(6MWT) in patients with pulmonary arterial hypertension
currently on optimized medical control compared to patients
who do not exercise?
Peter M. Gdovin, PA-S
A	
  SELECTIVE	
  EVIDENCE	
  BASED	
  MEDICINE	
  REVIEW	
  
In	
  Partial	
  Fulfillment	
  of	
  the	
  Requirements	
  For	
  	
  
The	
  Degree	
  of	
  Master	
  of	
  Science	
  
In
Health	
  Sciences	
  –	
  Physician	
  Assistant	
  
	
  
	
  
Department	
  of	
  Physician	
  Assistant	
  Studies	
  
Philadelphia	
  College	
  of	
  Osteopathic	
  Medicine	
  
Philadelphia,	
  Pennsylvania	
  
	
  
	
  
	
  
December	
  19,	
  2014	
  
	
  
	
  
	
  
	
  
	
  

	
  
ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
“Does a structured exercise intervention of at least ten weeks improve the distance
walked in a 6 minute walking test (6MWT) in patients with pulmonary arterial
hypertension currently on optimized medical control compared to patients who do not
exercise?”
STUDY DESIGN: Systematic review of two randomized controlled trials and a
prospective case study published between 2006-2013, all English language.
DATA SOURCES: Two randomized controlled studies and a prospective uncontrolled
trial which studied the effects of a structured exercise program of at least 10 weeks
duration were obtained using PubMed.
OUTCOMES MEASURED: The outcome of each study was the distance (measured in
meters) that each patient was able to walk during the 6 minute walking test as compared
to their baseline at the beginning of the study. The average of these participants were then
used to compare the control group versus the intervention group
RESULTS: Two randomized controlled trials and a uncontrolled prospective study were
used in this review. Mereles et al showed a difference between the control and exercise
group to be a mean of 111 m (95% CI, 65 to 139; P<0.001) after 15 weeks. Chat et al
found that there was a statistically significant mean increase of 45m with a 95% CI of 980m (p=0.003) in the exercise intervention group, and determined the number needed to
treat was 3 using dichotomous data. Grunig et al showed a significant mean increase
from baseline to 3-week testing (64 +/- 47m, p<0.001) and again from baseline to 15week (71 +/- 35m, p<0.003), with no control group studied.
CONCLUSIONS: All three studies demonstrated statistically significant improvement in
the distance walked in the six minute walking test after a structured exercise intervention
as compared to baseline testing, as well as compared to a control group. A structured
exercise intervention in patients with pulmonary arterial hypertension should be
considered as a useful addition to medical therapy.
KEY WORDS: pulmonary hypertension, exercise therapy, rehabilitation
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INTRODUCTION
While treating patients, it is often difficult to avoid frustration by the patient and
the provider when mainstay therapy does not return the patient to the level of function
which they desire. This is often the case with pulmonary arterial hypertension (PAH)
because it is not curable1, and the effects on a patient’s lifestyle can be devastating. PAH
is a chronic sustained elevated blood pressure in the pulmonary arteries, which leads to
stiffening of the pulmonary vasculature.1
The signs and symptoms of PAH may include dyspnea, chest pain, dizziness,
syncopal episodes, fatigue, peripheral edema, and a dry cough.2 Patients experiencing
symptoms at rest indicate severe disease.2 The New York Heart Association Functional
Classes are useful in categorizing patients because of the similarity of the symptoms
which are experienced in PAH.3 The NYHA functional classes are graded from I-IV
depending on severity of symptoms.3 There are several risk factors for developing PAH,
including female gender, family history, obstructive sleep apnea, pregnancy, living at
higher altitude, certain drugs such as methamphetamines, and other diseases such as
congenital heart disease, scleroderma, and lupus.2 The etiology for patients with PAH
include idiopathic PAH, hereditary PAH, or PAH due to diseases that localize to small
pulmonary arterioles, such as connective tissue diseases, HIV infection, portal
hypertension, congenital heart disease, schistosomiasis, and drug use.2
Although PAH is a relatively uncommon condition, with an estimated prevalence
of 12.4 cases per 1 million people in the United States and new diagnoses of 2.3 cases per
1 million, the severity of patient’s symptoms generally lead to a long hospitalizations and
crippling medical expenses.4 The average cost for the initial hospitalization for a patient
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with PAH was $30,286 with an average length of stay of 11 days.4 It is often difficult to
avoid the initial hospitalization since the condition and diagnosis is unknown to the
patient; however, once the diagnosis of PAH is made, proper medical management can
help to avoid subsequent admissions. The average cumulative cost per a rehospitalized
patient with PAH was $71,622, with an average length of stay of 24.5 days.4
The currently accepted therapies for PAH include calcium channel blockers,
digoxin, loop diuretics, home oxygen, and Coumadin2. Additional medical therapy
options include endothelin receptor agonists, phosphodiesterase inhibitors, prostacyclins,
and lung transplant in selected patients.2 Since PAH is not a curable condition, the goal
of treatment is to minimize patient’s symptoms and reduce the need for hospital
readmission. It was previously believed that exercise training would cause an increased
risk for sudden cardiac death in patients with PAH due to the sheer force on the
pulmonary arteries during exercise; however, recent studies in patients with left sided
heart failure have demonstrated the safety of exercise and have broken new grounds in
the ability to study exercise interventions in patients with chronic cardiopulmonary
disease.5 This systematic review will utilize two randomized controlled trials and an
uncontrolled prospective study evaluating the effect of a structured exercise intervention
on distance walked on a 6 minute walking test in patients with pulmonary arterial
hypertension currently on optimized medical therapy.
OBJECTIVE
Does a structured exercise intervention of at least ten weeks improve the distance
walked in a 6 minute walking test (6MWT) in patients with pulmonary arterial
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hypertension currently on optimized medical control compared to patients who do not
exercise?
METHODS
This systematic review will study the population of patients that are between the
ages of 18-80, who have previously been diagnosed with pulmonary arterial hypertension and are
currently on optimized medical therapy. The intervention being reviewed in this study is a
structured exercise intervention of at least 10 weeks duration. The comparison group was
patients with pulmonary arterial hypertension on current optimized medical control without a
structured exercise intervention. The outcome that was measured was the distance walked in the
6MWT after exercise intervention as compared to baseline 6MWT. Two randomized

controlled studies were used for analysis, as well as a prospective case study.
The key words used in the searches were “pulmonary hypertension,” “exercise
therapy,” and “rehabilitation.” All articles were originally published in peer reviewed
journals in the English language. The author searched articles via PubMed and Cochrane
library, and articles were selected based on their relevance to the clinical question.
Inclusion criteria consisted of studies which were published after 1999. Exclusion criteria
consisted of studies which had patients who were under the age of 18 or over the age of
80, or patients who had changed their medications used to control PAH within the
previous two months. The statistics of this study were analyzed using mean change from
baseline, NNT, p-values and 95% confidence interval.
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Table 1 - Demographics & Characteristics of included studies
# of
W
pati
Inclusion
Exclusion
/
Study Type ents Age
Criteria
Criteria
D

RCT,
cross
Merel
over
es,
single
2006
blind
(5)
ed
study

Chan,
2013
(6)

Gruni
g,
2012
(7)

Phase
2b
RCT,
single
blind
ed

Prosp
ective
Case
Study

32

26

22

18-75
yo

21-82
yo

18-80
yo

Three months
of optimized
medical
therapy, WHO
functional
class II-IV

Pulmonary
arterial
pressure
greater than 25
mmHg. WHO
functional
classes II-III.
Optimized
medical
therapy

WHO Class IIIV, optimized
medical
therapy

Active
lifestyle.
Recent
syncopal
episode.
Physical
ailment
preventing
exercise.
Medication
changes in
previous 3
months.
Medication
change in
previous
three
months.
Active
lifestyle.
Illicit drug
use,
tobacco
use, or
pregnancy.

Any
change in
medication
within the
previous
two
months.

2

3

1

Interventions
Inpatient exercise program
for 3 weeks which
includes: bicycle ergometer
for 10-25 minutes per day,
60 minutes of walking
preformed 5 days per
week. 5 days per week of
30 minute of resistance
training, and 30 minutes of
respiratory training
Patients continued cardio
and resistance training at
home for 12 weeks
following inpatient stay.
24-30 sessions of
medically supervised
treadmill walking for 30-45
minutes per session over
the course of 10 weeks.
Target heart rate intensity
ranged from 70-80% from
baseline maximums.
Experimental group also
received weekly
educational classes.
Exercise therapy consisted
of interval bicycle
ergometer training at low
workloads, mental gait
training, dumbbell-training
of single muscle groups
using low weights (500 to
1000 g) and respiratory
therapy 5 days/week. The
training was continued at
home with at least 30
minutes/day at 5 days/week
for the following 12 weeks.
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OUTCOMES MEASURES

Two randomized controlled studies and an uncontrolled prospective study were
used in this review and the outcome which was measured was patient oriented (POEM).
The outcome that was measured for this review was the distance (measured in meters)
that each patient was able to walk during the 6 minute walking test with a standard
deviation presented as (+/-), as compared to baseline at the beginning of the study. The
average of these participants were then used to compare the control group versus the
intervention group.
RESULTS
The study conducted by Mereles et al was a prospective randomized trial which
consisted of thirty patients with PAH, randomized into a control group (n=15), and a
treatment group (n=15). The intervention in this study was a structured exercise
intervention of three weeks duration in a hospital, followed by 12 additional weeks of self
guided training. The 6MWT was completed pre-intervention, at 3 weeks, and at 15
weeks, and the control group was allowed to cross over to the treatment group at the end
of week 15 (n=10).5
The initial control group and intervention group did not vary significantly in the
6MWT at baseline. After 3 weeks of treatment, the 6MWT increase was significantly
larger in the intervention group (85+/- 56 m) than in the control group (12 +/- 37 m;
P=0.0003).5 After 15 weeks, the 6MWT decreased in the control group (-15 +/- 54 m),
whereas patients in the primary training group revealed a further improvement (96+/- 61
m; P<0.0001).5 The difference between groups was a mean of 111 m (95% CI, 65 to
139; P<0.001).5 Patients in the crossover group improved similarly to the patients in the
initial intervention group, showing a significantly higher increase in the 6MWT after 3
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weeks (75 +/- 41 m, p<0.05) and after 15 weeks (mean 74 +/- 49 m, p<0.001) compared
with baseline.5 Overall, the treatment increased walking distance in the 6MWT by an
average of 96 m, an increase of 22%, when combining the data from the primary exercise
group and the crossover group.5 Individual patient data was not available to calculate
numbers needed to treat. P-values of less than 0.05 were considered significant. The
data in Tables 2-4 is provided from Mereles et al.
Table 2 –Comparison of Control Group vs Exercise Intervention after 3 and 15 weeks 5
3 week 6MWT
15 week 6MWT
change from baseline change from baseline
Baseline 6MWT (m) (m)
(m)
411 +/- 86
12 +/- 37
-15 +/- 54
Control (n=15)
Exercise
Intervention
439 +/- 52
85 +/- 56
96 +/- 61
(n=15)
0.38
0.003*
<0.0001*
p-value
Table 3 –Mean Difference, Confidence Interval, and P-value for Control vs Intervention5
Mean difference after 15 weeks (m)
95% CI (m)
p-value
111
65-139
<0.001*
Table 4 –Crossover Intervention Group Change from Baseline5
3 week 6MWT change from
15 week 6MWT change from
baseline (m)
baseline
Crossover exercise
75 +/- 41
74 +/- 49
group (n=10)
<0.05*
<0.001*
p-value
Chan et all conducted a randomized controlled trial which originally consisted of
twenty-six patients, divided into a treatment group (n=10) which received education and
a ten week exercise intervention and a control group (n=13) which only received
education. The intervention group had three patients eliminated from the trial before
analysis of the data, two patients due to changes in medications, and one because of less
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than 80% compliance with the exercise regimen.6 The 6MWT was completed at
baseline, and again at week ten.
At baseline, there was no significant difference between the interventional
(mean=411 +/- 73m) and control group (377 +/- 97m) in the 6MWT (p=0.183).6 The
intervention group showed a significant increase in distance walked after ten weeks of
training to 467 +/- 86m, with a p value of 0.002 compared to baseline.6 The control
group did not demonstrate a statistically significant increase in distance walked, with tenweek results at 389 +/- 107m with a p value of 0.134 as compared to baseline. The
difference between the groups was statistically significant, with a mean distance of 45m,
95% CI 9-80m, and a p value of 0.008.6 Using a significant improvement of greater than
or equal to 41m per individual, the results of the study was converted to dichotomous
data and was used to measure the numbers needed to treat (NNT=3). The data in Tables
5-7 is provided from Chan et al.
Table 5 – Baseline and 10-week 6MWT data for Control and Exercise Intervention6
Baseline 6MWT
10 week 6MWT
(m)
(m)
p-value
Control Group
377 +/- 97
389 +/- 107
0.134
(n=13)
Exercise Intervention
411 +/- 73
467 +/- 86
0.002*
Group (n=10)
0.183
p-value
Table 6 – Mean Difference, Confidence Interval, and p-value for Exercise Intervention6
Mean Difference (m)
95% CI
p-value
45
9-80m
0.008
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Table 7 – Calculation of Numbers Needed to Treat6
Relative
Absolute
Benefit
Benefit
Increase (RBI) Increase (ABI)
(EER - CER) /
CER
EER
EER-CER
CER
6/10 =
3/13 = 23.1%
1.6
0.369
60%

Number Needed
to Treat (NNT)
1/ABI
2.71 = 3 patients

Grunig et al conducted a prospective, uncontrolled trial utilizing the same
methods as Mereles et al; however, there was no control group. There were initially 22
patients in the trial; however, one patient dropped out of the study due to an upper airway
infection. The baseline average distance walked in the 6MWT was 386 +/- 121m. After
3 weeks, the mean distance walked increased significantly by 64 +/- 47 meters (P <
0.001) and by 71 ± 35 meters after 15 weeks (P < 0.003).7 Only one patient in the trial
did not show an increase in distance walked from baseline, likely due to hip
osteoarthritis.7 Nine patients were lost to follow up at 15 weeks, likely due to distance
needed to travel to complete the study. Results remained significant after multiple
imputations of missing values for the 6MWD at 15 weeks using the predictive mean
managing model. The data in Table 8 was taken from Grunig et al.
Table 8 – Mean Distance Walked in 6MWT at Baseline, 3 weeks, and 15 weeks
Baseline 6MWT
Change from Baseline
Change from Baseline at
Mean (m)
at 3 week 6MWT (m)
15 week 6MWT (m)
386 +/- 121
64 +/- 47
71 +/- 35
p-value
<0.001*
<0.003*
DISCUSSION
Although each of the three studies in this review demonstrated statistically
significant improvements from baseline for patients with pulmonary arterial
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hypertension, there were a few factors that may impact the significance of these studies.
First, the six-minute walking test has long been thought to be the best test to determine
the effectiveness of a medical intervention for patients with cardiopulmonary disease;
however, there are a few critics that suggest that the 6MWT is too short in duration to
gain any meaningful data for the effectiveness of the trial.8 Since this review is focused
solely on patient oriented outcomes, this criticism was not taken into account when
determining significance of this study.
Another factor which should be considered is the multiple etiologies of
pulmonary hypertension.2 These three studies consisted of a heterogeneous group of
patient with different etiologies for pulmonary hypertension. Since each of the studies
demonstrated significant improvement in the 6MWT in the exercise intervention group, it
could be hypothesized that all etiologies of pulmonary hypertension would benefit from
an exercise intervention. Also, patients were taken from all functional classes before
intervention, thus results cannot be generalized across functional classes.3 Further
studies with homogenous etiologies of pulmonary hypertension should be considered to
determine the effectiveness of exercise intervention.
Finally, because of the nature of this intense exercise intervention and the
inpatient component of the program, it may be too expensive to safely provide an
exercise intervention for patients with pulmonary hypertension. It is likely that insurance
companies would not pay for patients to receive long-term inpatient rehabilitation in the
United States, as well as paying for maintenance therapy once the initial intervention is
complete6. If insurance companies will not cover the therapy, it is likely too expensive
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for patients to consider exercise intervention as a safe method for improvement of
symptoms of pulmonary hypertension.
The results of exercise intervention as compared to pharmaceutical treatment for
pulmonary hypertension suggest that exercise intervention may be more effective in
improving the 6MWT than drug therapy. In fact, the treatment-related increase in
walking distance of 96 m (22%) observed in Mereles et al was higher than the increases
observed with the use of sildenafil9, oral epoprostenol10, inhaled iloprost11, and oral
bosentan12.
There were also a few limitations of these studies as well. Because of the nature
of the studies, it was impossible to complete a blinded study with the exercise
intervention. This could potentially lead to incentive for extra encouragement for the
exercise intervention groups. In addition, there was no control group for the study
completed by Grunig et al. Finally, each of the studies had small sample sizes, which
could have skewed the data. There were only 74 patients combined in this systematic
review, with only 28 patients confined to the control groups5,6,7. To be sure of these
results, future studies should be designed to attract more patients with pulmonary
hypertension to participate.
CONCLUSION
The findings of these three studies have demonstrated that there is a statistically
significant increase in distance walked in the six-minute walking test from baseline after
the conclusion of a structured exercise intervention of at least ten weeks in patients with
pulmonary arterial hypertension, currently on optimized medical control compared to
patients who do not exercise5,6,7.
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Future studies should be conducted to determine the significance of exercise

intervention for individual etiologies of pulmonary arterial hypertension, as well as the
effect of exercise intervention on each specific functional class of the disease. There are
not any ongoing trials studying exercise intervention in pulmonary arterial hypertension
at this time.
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